Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 401 to 450 of 719 results for pain management

  1. Manual therapies for chronic primary pain: What is the clinical and cost effectiveness of manual therapy for managing chronic primary pain in people aged 16 years and over?

    therapies for chronic primary pain: What is the clinical and cost effectiveness of manual therapy for managing chronic primary...

  2. Relaxation therapy for chronic primary pain: What is the clinical and cost effectiveness of relaxation therapies for managing chronic primary pain in people aged 16 years and over?

    therapy for chronic primary pain: What is the clinical and cost effectiveness of relaxation therapies for managing chronic primary...

  3. Transcranial magnetic stimulation for chronic primary pain: What is the clinical and cost effectiveness of transcranial magnetic stimulation for managing chronic primary pain in people aged 16 years and over?

    chronic primary pain: What is the clinical and cost effectiveness of transcranial magnetic stimulation for managing chronic primary...

  4. Repeat courses of acupuncture for chronic primary pain: What is the clinical and cost effectiveness of repeat courses of acupuncture or dry needling for managing chronic primary pain in people aged 16 years and over?

    chronic primary pain: What is the clinical and cost effectiveness of repeat courses of acupuncture or dry needling for managing chronic...

  5. Laser therapy for chronic primary pain: What is the clinical and cost effectiveness of laser therapy for managing chronic primary pain in people aged 16 years and over?

    therapy for chronic primary pain: What is the clinical and cost effectiveness of laser therapy for managing chronic primary...

  6. Psychological therapy – mindfulness for chronic primary pain: What is the clinical and cost effectiveness of mindfulness therapy for managing chronic primary pain in people aged 16 years and over?

    mindfulness for chronic primary pain: What is the clinical and cost effectiveness of mindfulness therapy for managing chronic primary...

  7. Factors affecting participation and quality of life:- What are the key factors, including additional care and support, that influence participation and quality of life in people with neuropathic pain?

    neuropathic pain? Any explanatory notes(if applicable) Why this is important:- There is evidence suggesting that people with neuropathic...

  8. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

  9. Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

    This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

  10. Endoscopic transluminal pancreatic necrosectomy (HTG421)

    Evidence-based recommendations on endoscopic transluminal pancreatic necrosectomy in adults. This involves removing dead tissue from the pancreas.

  11. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  12. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The World...

  13. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  14. Thoracoscopic repair of congenital diaphragmatic hernia in neonates (HTG247)

    Evidence-based recommendations on thoracoscopic repair of congenital diaphragmatic hernia in neonates. This involves inserting surgical instruments through small cuts in the chest, and then moving the abdominal organs out of the chest and repairing the diaphragm.

  15. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (HTG222)

    Evidence-based recommendations on percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. This involves using a special device to block the mouth of the left atrial appendage and stop the blood clot from getting into the bloodstream.

  16. Thyroid cancer: assessment and management (NG230)

    This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.

  17. FreeStyle Libre for glucose monitoring (MIB110)

    NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .

  18. Potential for dependence associated with pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for neuropathic...

  19. Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness...

  20. Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

    Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.

  21. Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation (HTG180)

    Evidence-based recommendations on thoracoscopic epicardial radiofrequency ablation for atrial fibrillation. This involves using heat to destroy the selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.

  22. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's (HTG733)

    Evidence-based recommendations on MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson’s. This involves using ultrasound to destroy tissue in the thalamus.

  23. Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example pregabalin) reduce the frequency or severity of neuropathic pain in people with spinal cord injury?

    Recommendation ID NG41/1 Question Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example...

  24. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

  25. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  26. Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain?

    Question Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain? Any explanatory notes(if...

  27. Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)

    Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults.

  28. Chemical sympathectomy for managing critical limb ischaemic pain:- What is the clinical and cost effectiveness of chemical sympathectomy in comparison with other methods of pain control for managing critical limb ischaemic pain?

    critical limb ischaemic pain:- What is the clinical and cost effectiveness of chemical sympathectomy in comparison with other methods of...

  29. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    neuropathic pain? Any explanatory notes(if applicable) Why this is important Combination therapy is commonly prescribed for neuropathic...

  30. Extracorporeal carbon dioxide removal for acute respiratory failure (HTG703)

    Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.

  31. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (HTG643)

    Evidence-based recommendations on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine in adults. This involves attaching a small device on the forehead to send small electrical currents to the nerves that bring sensation to the upper eyelids, forehead and scalp.

  32. Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease (HTG749)

    Evidence-based recommendations on laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. This involves placing an implant on the outside of the upper part of the stomach wall using keyhole surgery.

  33. Attention deficit hyperactivity disorder: diagnosis and management (NG87)

    This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.

  34. Managing breakthrough pain:- What is the acceptability, safety, and effectiveness of different types of opioid analgesia for breakthrough pain in children and young people with life-limiting conditions who are having end of life care in the community?

    Managing breakthrough pain:- What is the acceptability, safety, and effectiveness of different types of opioid analgesia for...

  35. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

  36. Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)

    This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.

  37. Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    neuropathic pain? Any explanatory notes(if applicable) There has been some suggestion that some pharmacological agents for neuropathic...

  38. Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment (HTG760)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.

  39. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)

    Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.

  40. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    quality of life in neuropathic pain? Any explanatory notes(if applicable) Pharmacological agents for neuropathic pain are...

  41. Permacol for treating anal fistulae (MIB105)

    NICE has developed a medtech innovation briefing (MIB) on Permacol for treating anal fistulae .

  42. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  43. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  44. Impact of drug-related adverse effects on cost effectiveness and quality of life:- What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    in neuropathic pain? Any explanatory notes(if applicable) Why this is important:- Pharmacological agents for neuropathic...

  45. Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    CG173/2 Question Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment...

  46. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

  47. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

  48. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  49. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    Question What is the clinical and cost effectiveness of opioids for the management of acute sciatica? Any explanatory notes(if...

  50. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    What is the clinical and cost effectiveness of antidepressants for the management of sciatica? Any explanatory notes(if applicable) Why...